Agent Capital

Agent Capital, founded in 2017 and headquartered in Waltham, is a venture capital firm that specializes in investing in healthcare-related companies at various stages of development across the United States. Their focus is on supporting biotech companies in the early-to-late stages to help them achieve their growth and innovation goals.

Vissaagan Gopalakrishnan

Associate

Preston Noon

Partner, Co-Founder

Bruce Peacock

Venture Partner & Operating Partner

Geeta Vemuri

Managing Partner, Founder

42 past transactions

Cyrus Biotechnology

Series B in 2021
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Vittoria Biotherapeutics

Seed Round in 2022
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Pliant Therapeutics

Private Placement in 2019
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Metagenomi

Series A in 2019
Metagenomi, Inc. develops gene editing systems for the treatment of genetic diseases. The company was incorporated in 2016 and is based in Emeryville, California.

Dragonfly Therapeutics

Venture Round in 2017
Dragonfly Therapeutics, Inc. develops drugs to stimulate immune responses against cancer using its platform TriNKET. Dragonfly Therapeutics, Inc. has strategic collaborations with Celgene Corporation and Merck. The company was founded in 2015 and is based in Waltham, Massachusetts.

Pyxis Oncology

Private Placement in 2019
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Palvella Therapeutics, Inc.

Private Placement in 2020
Palvella Therapeutics, Inc., a biopharmaceutical company, develops and commercializes pathogenetically targeted therapies for serious and rare genodermatoses diseases. It offers QTORIN, an anhydrous gel that comprises excipients selected in an optimized ratio to achieve drug stability at room temperature and enable cutaneous distribution into the keratinocytes in the basal layer of the epidermis and to the reticular dermis, where the pathology manifests in various dermatologic conditions. Palvella Therapeutics, Inc. was founded in 2015 and is based in Wayne, Pennsylvania.

Pliant Therapeutics

Series B in 2018
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Palvella Therapeutics

Series C in 2020
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

ImCheck Therapeutics

Series B in 2019
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

ImCheck Therapeutics

Private Placement in 2019
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

Verge Genomics

Series A in 2018
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.

Pyxis Oncology

Series A in 2019
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Carisma Therapeutics

Series B in 2021
CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Precision BioSciences

Private Placement in 2018
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

Carisma Therapeutics

Private Placement in 2018
CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Cerevance

Series B in 2024
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Jana Care

Series B in 2023
Jana Care works to reverse diabesity, the twin epidemic of diabetes and obesity, by embedding mobile technology with diagnostics and proven behavior change science. The company offers a sensor platform that enables its users to measure multiple blood parameters, including blood glucose; HbA1C; lipids- HDL, LDL, and TrG; creatinine; hemoglobin; and more. It then feeds into a web-based platform to provide its users with actionable and continuous feedback for positive behavior change. Jana Care was founded in 2011 and is based in Newton, Massachusetts.

Affini-T Therapeutics

Venture Round in 2022
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Metagenomi

Series A in 2020
Metagenomi, Inc. develops gene editing systems for the treatment of genetic diseases. The company was incorporated in 2016 and is based in Emeryville, California.

Carbon Biosciences

Series A in 2022
Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.

Orchard Therapeutics

Private Placement in 2018
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orchard Therapeutics

Series B in 2017
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orbus Therapeutics

Series B in 2017
They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

Carisma Therapeutics

Series C in 2022
CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Pliant Therapeutics

Private Placement in 2018
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Skyhawk Therapeutics

Venture Round in 2018
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Metagenomi

Private Placement in 2020
Metagenomi, Inc. develops gene editing systems for the treatment of genetic diseases. The company was incorporated in 2016 and is based in Emeryville, California.

Entrada Therapeutics

Series A in 2018
Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Interius BioTherapeutics

Private Equity Round in 2020
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.

Carisma Therapeutics

Series A in 2018
CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics

Series B in 2021
CARISMA Therapeutics Inc., a biotechnology company, develops CAR macrophages, an approach to immunotherapy. CARISMA Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to CARISMA Therapeutics Inc. in June 2018. The company was incorporated in 2016 and is headquartered in Philadelphia, Pennsylvania.

Verge Genomics

Private Placement in 2018
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.

Skyhawk Therapeutics

Private Placement in 2018
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Q32 Bio

Post in 2024
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Vittoria Biotherapeutics

Venture Round in 2023
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Foresight Diagnostics

Series B in 2023
Developer of a novel diagnosis technology designed to detect cancers earlier from a simple blood sample. The company's technology uses the biological features that make each cancer type and each individual person's cancer unique by focusing on the things that differentiate a cancer cell from a healthy cell, enabling healthcare professionals to conduct diagnoses of early smaller tumors and apply personalized and effective cancer treatment strategies for patients.

Palvella Therapeutics

Series D in 2023
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.